Webinar: RNA Approach to Rare Cardiomyopathies

Join Atrium Therapeutics August 19, 2026 at 6pm ET for an introduction to the company and its mission to pioneer targeted RNA delivery directly to the heart, transforming care for people living with rare, life-threatening genetic cardiomyopathies. Hear how Atrium's lead programs - ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy - are designed to address the underlying genetic drivers of these conditions for the first time. Leading genetic cardiomyopathy RNA researchers will share how RNA therapies can help cardiomyopathy patients. RNA therapies use ribonucleic acid molecules to prevent or treat diseases directly by influencing genetic messaging. Presenters: Dr. Husam Younis, the Chief Scientific Officer at Atrium Therapeutics, with more than 20 years of experience in drug discovery and development, including in rare disease. Another presenter will be announced soon. Registration is required: https://geneticcardiomyopathy.org/resources/upcoming-webinars/

Join Atrium Therapeutics August 19, 2026 at 6pm ET for an introduction to the company and its mission to pioneer targeted RNA delivery directly to the heart, transforming care for people living with rare, life-threatening genetic cardiomyopathies. Hear how Atrium's lead programs - ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy - are designed to address the underlying genetic drivers of these conditions for the first time. Leading genetic cardiomyopathy RNA researchers will share how RNA therapies can help cardiomyopathy patients. RNA therapies use ribonucleic acid molecules to prevent or treat diseases directly by influencing genetic messaging. Presenters: Dr. Husam Younis, the Chief Scientific Officer at Atrium Therapeutics, with more than 20 years of experience in drug discovery and development, including in rare disease. Another presenter will be announced soon. Registration is required: https://geneticcardiomyopathy.org/resources/upcoming-webinars/